Accuray Incorporated ARAY recently introduced the CyberKnife S7 System — the next generation CyberKnife platform. This new CyberKnife technology is the most recent instance of the company’s innovation in radiation therapy that enables healthcare providers in offering best care to their patients on the back of new capabilities. This new system is likely to boost Accuray’s CyberKnife Systems product line.
Notably, the CyberKnife platform is a fully robotic, non-invasive radiation therapy device, which is able to treat cancerous and benign tumors in the body, and neurological disorders.
CyberKnife S7 System at a Glance
The new system is an innovative device that combines speed, advanced precision and real-time artificial intelligence (AI)-driven motion tracking and synchronization treatment delivery for all stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments. Interestingly, all of this can be done in just 15 minutes.
Benefits of the System
The CyberKnife S7 System has been developed primarily for the speed, operational efficiency and accuracy necessary for clinicians, making it the only device capable of delivering sub-millimetric stereotactic treatments anywhere in the body without any human intervention.
With the help of this new system, patients can benefit from a shorter overall course of treatment and a substantial reduction in the risk of side effects that can significantly impact patients’ lives.
Notably, Geisinger Wyoming Valley Medical Center will be the first in the world to treat patients with the new system.
In February 2020 the company installed the first CyberKnife M6 System in Mercy Hospital, St. Louis Missouri. This next-generation CyberKnife System can deliver accurate stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments with ease, thereby enabling the clinical team to expand access to one of the most advanced methods for administering radiation to more cancer patients.
Per a Medgadget report, the global radiotherapy market is estimated to grow at a rate of 4.7% over the forecast period (2019-2025). Rise in technological advancements, increasing prevalence of cancer and rising healthcare expenditure are the primary factors driving the market.
Shares of the Zacks Rank #2 (Buy) stock have gained 38.4% in the past three months, compared with the industry’s rally of 29.6%.
Other Key Picks
Some other top-ranked stocks from the broader medical space include Quest Diagnostics Incorporated DGX, Laboratory Corporation of America Holdings LH and West Pharmaceutical Services, Inc. WST. While West Pharmaceutical sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and Laboratory Corporation carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has a projected long-term earnings growth rate of 9.2%.
Quest Diagnostics has an estimated long-term earnings growth rate of 7.6%.
Laboratory Corporation has an estimated long-term earnings growth rate of 6.1%.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This young company’s gigantic growth was hidden by low-volume trading, then cut short by the coronavirus. But its digital products stand out in a region where the internet economy has tripled since 2015 and looks to triple again by 2025.
Its stock price is already starting to resume its upward arc. The sky’s the limit! And the earlier you get in, the greater your potential gain.
Click Here, See It Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Accuray Incorporated (ARAY) : Free Stock Analysis Report
Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report
Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report
West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research